Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03603600 · ClinicalTrials.gov registry record · NA

Evaluate the Safety and Effectiveness of the enVista® One-Piece Hydrophobic Acrylic Trifocal Intraocular Lens

A NA study, sponsored by Bausch & Lomb Incorporated.

Completed
Registry status
NA
Development phase
501
Enrollment target

NCT03603600 is a NA study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 501 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03603600, a NA study, has completed, sponsored by Bausch & Lomb Incorporated.

COMPLETED
Registry status
NA
Development phase
501 participants
Enrollment target

Study Summary

The objective of the study is to evaluate the safety and effectiveness of the enVista trifocal intraocular lens when implanted in the capsular bag.

Interventions

  • DEVICE enVista MX60E
  • DEVICE enVista MX60EF

Trial Details

FieldValue
Enrollment Target 501 participants
Start Date 2018-05-31
Est. Completion 2023-05-04
Phase NA

Sponsor

Bausch & Lomb Incorporated

174 total trials

What the Registry Record Tells You About NCT03603600

The ClinicalTrials.gov registry entry for NCT03603600 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 501 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which enVista MX60E is the first listed.

NCT03603600 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03603600 about?

NCT03603600 is a clinical study titled "Evaluate the Safety and Effectiveness of the enVista® One-Piece Hydrophobic Acrylic Trifocal Intraocular Lens". The objective of the study is to evaluate the safety and effectiveness of the enVista trifocal intraocular lens when implanted in the capsular bag.

What is the current status of trial NCT03603600?

This trial is currently completed. It is a NA study. The enrollment target is 501 participants. The study started on 2018-05-31. Estimated completion is 2023-05-04.

What interventions are being tested in trial NCT03603600?

The interventions under investigation include: enVista MX60E (DEVICE), enVista MX60EF (DEVICE).

Who is sponsoring clinical trial NCT03603600?

This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.